Core Viewpoint - The document outlines the fundraising management measures of Yifan Pharmaceutical Co., Ltd., emphasizing the need for strict adherence to regulations and efficient use of raised funds to protect investors' rights and interests [3][4][11]. Summary by Sections General Principles - The purpose of the fundraising management measures is to standardize the management and use of raised funds, improve efficiency, and protect investors' rights [3]. - The term "raised funds" refers to money obtained through the issuance of stocks or other equity-like securities, excluding funds raised for equity incentive plans [3]. - The company must use raised funds prudently and ensure that their use aligns with the commitments made in the issuance application documents [3][4]. Fund Storage - The company is required to open a special account for raised funds, which must be approved by the board of directors, and these funds should not be mixed with other funds [5][6]. - A tripartite supervision agreement must be signed with the underwriter or independent financial advisor and the bank holding the funds within one month of the funds being received [6][7]. Fund Usage - Raised funds should primarily be used for the company's main business and must not be used for high-risk investments or to provide financial assistance to others [8][9]. - If the investment project cannot be completed within the original timeframe, the company must disclose the reasons and the current status of the funds [8][9]. - Any changes in the use of raised funds must be approved by the board and disclosed promptly [9][10]. Supervision and Reporting - The company’s accounting department must maintain detailed records of the use of raised funds, and internal audits should be conducted quarterly [28][29]. - The board must regularly review the status of the raised funds and report any significant discrepancies in usage compared to the planned investment [29][30]. - Independent auditors must verify the annual report on the management and use of raised funds, and any adverse conclusions must be addressed by the board [20][21].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002922 证券简称：伊戈尔 公告编号：2025-064 伊戈尔电气股份有限公司 关于设立募集资金专户并签订三方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意伊戈尔电气股份有限公司向特定对象发行股票注册的批 复》（证监许可〔2025〕1509号）同意注册，公司向特定对象发行人民币普通股股票29,563,933股，每 股面值1元，每股发行价13.53元，募集资金总额为400,000,013.49元，扣除各项发行费用8,031,567.64元 （不含税）后的募集资金净额为人民币391,968,445.85元。上述募集资金已于2025年8月11日划至公司指 定账户，经容诚会计师事务所（特殊普通合伙）审验后于2025年8月11日出具了《验资报告》（容诚验 字[2025]518Z0100号）。 二、设立募集资金专户及签订监管协议的情况 2、甲乙双方应当共同遵守《中华人民共和国票据法》《支付结算办法》《人民币银行结算账户管理办 法》 ...

Fundraising Overview - The company raised a total of RMB 455.5322 million through its initial public offering, with a net amount of RMB 390.9331 million after deducting various issuance costs [1][2] - The funds were raised by issuing 20.200986 million shares at a price of RMB 22.55 per share [1] Fund Utilization and Balance - As of December 31, 2022, the company had a remaining balance of RMB 336.43 million in its fundraising account, with RMB 4.70846 million used for projects and RMB 1.69811 million for issuance costs [2] - By December 31, 2023, the remaining balance was RMB 236.3034 million, with RMB 9.35421 million utilized for projects [2] - As of December 31, 2024, the remaining balance was RMB 137.4138 million, with RMB 8.77753 million used for projects [2] - As of June 30, 2025, the remaining balance was RMB 114.5452 million, with RMB 2.37295 million utilized for projects [2] Fund Management - The company has established a fundraising management system to ensure the effective use of funds and protect investor rights [3] - Funds are stored in designated bank accounts, and a tripartite supervision agreement has been signed with the underwriter and banks [3] Project Completion and Remaining Payments - Several projects funded by the raised capital, including the R&D center and marketing network construction, have been completed, with remaining payments totaling RMB 30.1286 million [2][3] - The company has used part of the raised funds to replace self-raised funds for issuance costs, amounting to RMB 4.6433 million [6][11] Idle Fund Management - The company has approved the use of idle funds for cash management, with a limit of RMB 100 million [5][6] - As of June 30, 2025, RMB 42 million of idle funds were allocated for cash management [12]

Core Viewpoint - Guangzhou Duople Electronic Technology Co., Ltd. has established a special account for raised funds to support the "Non-destructive Testing Intelligent Production Base Construction Project" and has signed a tripartite supervision agreement for fund management [1][6]. Fundraising Overview - The company has received approval from the China Securities Regulatory Commission for its initial public offering (IPO), issuing 15.5 million shares at a price of RMB 71.80 per share, raising a total of RMB 1,112.90 million. After deducting issuance costs of approximately RMB 104.98 million, the net amount raised is RMB 1,007.92 million [1][2]. - The funds have been verified by a third party, and a verification report has been issued [1]. Previous Fundraising Account Setup - To ensure proper management and usage of raised funds, the company has established special accounts with several banks and signed tripartite supervision agreements [2][3]. - The total amount stored in previous fundraising accounts is RMB 823.11 million, allocated for various projects including the headquarters building and the non-destructive testing production base [4][5]. New Fundraising Account and Agreement - A new special account has been set up with CITIC Bank for the non-destructive testing project, with a tripartite supervision agreement signed between the company, CITIC Bank, and the sponsor, Great Wall Securities [6][7]. - The agreement stipulates that the special account is exclusively for the designated project, with strict controls on fund withdrawals and usage [7][8]. Agreement Details - The agreement includes provisions for fund management, requiring the company to provide documentation for fund usage and allowing the supervising party to conduct audits and inquiries [9][11]. - The agreement will remain in effect until all funds are utilized and the account is closed, with provisions for dispute resolution [12].

吉林省西点药业科技发展股份有限公司 第一章 总 则 第一条 为规范和完善吉林省西点药业科技发展股份有限公司（以下简称公 司）募集资金存储、使用、变更、监督和责任追究的制度，明确募集资金使用的 分级审批权限、决策程序、风险控制措施及信息披露要求，保证募集资金项目的 正常进行和有效管理，提高募集资金使用效率，保护股东权益，根据《中华人民 共和国公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》 《上市公司募集资金监管规则》等法律法规、规范性文件及《吉林省西点药业科 技发展股份有限公司章程》（以下简称《公司章程》）规定，制定本制度。 第二条 本制度所称募集资金是指公司通过发行股票或者其他具有股权性质 的证券，向投资者募集并用于特定用途的资金，但不包括上市公司实施股权激励 计划募集的资金。 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主 营业务，有利于增强公司竞争能 ...

东莞证券股份有限公司 关于东莞怡合达自动化股份有限公司 年度募集资金存放与使用情况进行了审慎核查，核查情况及核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据公司第二届董事会第二十二次会议、2023 年第一次临时股东大会、第二 届董事会第二十四次会议、第三届董事会第七次会议和 2024 年第二次临时股东大 会审议通过，并经中国证券监督管理委员会于 2024 年 5 月 16 日出具的《关于同意 东莞怡合达自动化股份有限公司向特定对象发行股票注册的批复》 （证监许可〔2024〕 元，发行价格为 15.09 元/股，实际募集资金总额为人民币 870,010,811.28 元，扣除 各项发行费用人民币 5,600,787.53 元（不含增值税）后，募集资金净额为人民币 由其出具了"信会师报字[2024]第 ZI10538 号"验资报告。 （二）募集资金使用和结余情况 | | 金额单位：人民币元 | | | | --- | --- | --- | --- | | 项目 | 序号 | 金额 | | | 募集资金总额 | A1 | 870,010,811.28 | | | 减：发行费用 | ...

Core Viewpoint - The company has reported on the status of its fundraising and the use of raised funds, highlighting the completion of several investment projects and the reallocation of surplus funds to enhance operational efficiency and meet market demands [3][16][21]. Group 1: Fundraising Overview - The company raised a total of RMB 3,201,044,000 through the issuance of 41,800,000 shares at a price of RMB 76.58 per share, with a net amount of RMB 3,035,261,414 after deducting issuance costs [3][16]. - The funds were fully deposited into a designated account by August 10, 2021, and have been verified by an accounting firm [3][16]. Group 2: Fund Usage and Surplus - As of June 30, 2025, the company has utilized RMB 2,165,506,830.13 of the raised funds, with a remaining balance of RMB 163,051,907.75 [5][6]. - The company has implemented a management system for the raised funds to ensure compliance with regulations and protect investor interests [5][6]. Group 3: Project Completion and Fund Reallocation - The company has completed the "Smart Audio Chip R&D and Industrialization Project," "5G RF Device R&D and Industrialization Project," and "Motor Driver Chip R&D and Industrialization Project," allowing for the reallocation of surplus funds to the "High-Performance Analog Chip R&D and Industrialization Project" [16][21]. - The surplus funds amounting to RMB 20,075.57 million will be used to support further R&D and upgrades in the high-performance analog chip sector [21][23]. Group 4: Project Delays and Adjustments - The timeline for the "High-Performance Analog Chip R&D and Industrialization Project" has been extended to December 2027 to accommodate market demands and project complexities [23][25]. - The company has made adjustments to its project plans based on market conditions and strategic goals, ensuring efficient resource allocation [21][23]. Group 5: Monitoring and Compliance - The company has established monitoring protocols and agreements with banks to ensure the proper use of raised funds, complying with regulatory requirements [5][6][46]. - The board and supervisory committee have approved the use of idle funds for temporary operational needs, ensuring that this does not affect the planned investment projects [38][52].

Core Viewpoint - The company, Shandong Tenda Fastening Technology Co., Ltd., has released its 2025 semi-annual report, detailing its financial performance, fundraising activities, and future plans, emphasizing the importance of accurate and complete information disclosure [1][22][27]. Group 1: Fundraising Overview - The company successfully raised a total of RMB 849 million through its initial public offering, with a net amount of RMB 767.72 million after deducting issuance costs of RMB 81.28 million [6][7]. - As of June 30, 2025, the company has RMB 276.08 million in unutilized fundraising, with RMB 51.08 million in the special fundraising account and RMB 225 million temporarily idle for cash management [16]. Group 2: Fund Management and Usage - The company has established a fundraising management system to ensure the proper use of funds, adhering to relevant laws and regulations [8]. - A tripartite supervision agreement has been signed with banks and the sponsor to ensure the funds are used appropriately [9]. - The company has utilized RMB 206.72 million for supplementary working capital, with a minor excess of RMB 0.43 million sourced from interest income [25]. Group 3: Project Funding and Adjustments - The company has approved the use of RMB 100 million to increase capital and provide RMB 150 million in interest-free loans to its wholly-owned subsidiary for project implementation [18]. - There have been no changes in the implementation location or methods for the fundraising projects as of June 30, 2025 [10]. - The company has postponed the expected operational status of certain projects to July 19, 2026, without altering the project subjects or total investment amounts [20]. Group 4: Board Meeting and Approvals - The board of directors convened on August 13, 2025, to review and approve the semi-annual report and the special report on fundraising storage and usage [26][29]. - All board members were present, and the meeting complied with legal and regulatory requirements [26].

Group 1 - The company, Tianjin ZHONGXIN Pharmaceutical Group Co., Ltd., has announced the closure of certain fundraising accounts as part of its financial management strategy [1][5]. - The company raised a total of RMB 836,079,987.68 through a non-public offering of shares in June 2015, with a net amount of RMB 814,340,000.00 after deducting various fees [2]. - The company has established a fundraising management method to ensure compliance with relevant laws and regulations, enhancing the efficiency of fund usage and protecting investor rights [3]. Group 2 - As of the announcement date, the company has completed the closure of specific fundraising accounts related to projects such as the "Terminal Marketing Network and Promotion System Project" and the "Bozhou Industrial Park Construction Project" [5]. - The company has transferred surplus funds and interest generated from the fundraising to its respective accounts and has terminated the regulatory agreements associated with the closed accounts [5]. - The company’s name was officially changed to Tianjin ZHONGXIN Pharmaceutical Group Co., Ltd. on May 18, 2022 [4].

Group 1 - The company has approved the temporary use of idle raised funds amounting to 298 million yuan to supplement working capital, with a repayment deadline of January 19, 2026 [1] - As of the announcement date, the company has repaid a total of 15 million yuan of the raised funds, with 283 million yuan remaining to be repaid before the deadline [2] - The company assures that the use of idle funds will not affect the normal progress of the investment projects funded by the raised capital [1][2] Group 2 - The board of directors of the company confirmed the proper arrangement and use of the funds during the temporary supplementation period [1] - The company will disclose information promptly if the balance in the special account for raised funds is insufficient for normal payments [2] - The announcement was made on August 13, 2025, by the board of directors of the company [4]